Population pharmacokinetics of gentamicin and dosing optimization for infants

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 482-489

  Medellín Garibay, Susanna E ^a   Rueda Naharro, Aída ^b   Peña Cabia, Silvia ^b   Garcí, Benito ^b   Romano Moreno, Silvia ^a   Barcia, Emilia ^c  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b HOSPITAL SEVERO OCHOA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GENTAMICIN; ANTIINFECTIVE AGENT; PHARMACOLOGICAL BIOMARKER;

ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG MONITORING; FEMALE; HUMAN; INFANT; MALE; MEDICAL RECORD; POPULATION RESEARCH; VOLUME OF DISTRIBUTION; BLOOD; DOSE RESPONSE; DRUG ADMINISTRATION; METABOLISM; NEWBORN; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; BIOMARKERS, PHARMACOLOGICAL; BODY WEIGHT; CHILD, PRESCHOOL; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GENTAMICINS; HUMANS; INFANT; INFANT, NEWBORN; MALE; RETROSPECTIVE STUDIES;

EID: 84920193062     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03464-14     Document Type: Article

References (32)

1. st century? Curr Opin Infect Dis 26:516-525. http://dx.doi .org/10.1097/QCO.0000000000000012.
2. Kumana CR, Yuen KY. 1994. Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs 47:902-913.
3. Warchol ME. 2010. Cellular mechanisms of aminoglycoside ototoxicity. Curr Opin Otolaryngol Head Neck Surg 18:454-458. http://dx.doi.org/10 .1097/MOO.0b013e32833e05ec.
4. Huth ME, Ricci AJ, Cheng AG. 2011. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol 2011: 937861. http://dx.doi.org/10.1155/2011/937861.
5. th ed. Churchill Livingstone, New York, NY.
6. Dobie RA, Black FO, Pezsnecker SC, Stallings VL. 2006. Hearing loss in patients with vestibulotoxic reactions to gentamicin therapy. Arch Otolaryngol Head Neck Surg 132:253-257. http://dx.doi.org/10.1001 /archotol.132.3.253.
7. th ed. Leximcomp, Hundson, OH.
8. Anderson BJ, Holford NH. 2009. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24:25-36. http://dx.doi.org/10.2133/dmpk.24.25.
9. U.S.FDA. 1998.Guidancefor industry: general considerations for pediatric pharmacokinetic studies for drugs and biological products. U.S. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/drugs /guidancecomplianceregulatoryinformation/guidances/ucm072114.pdf.
10. Anderson GD, Lynn AM. 2009. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy 29:680-690. http: //dx.doi.org/10.1592/phco.29.6.680.
11. Touw DJ, Westerman EM, Sprij AJ. 2009. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet 48:71-88. http://dx .doi.org/10.2165/00003088-200948020-00001.
12. Milsap RL, Jusko WJ. 1994. Pharmacokinetics in the infant. Environ Health Perspect 102(Suppl 11):S107-S110.
13. Best EJ, Gazarian M, Cohn R, Wilkinson M, Palasanthiran P. 2011. Once-daily gentamicin in infants and children: a prospective cohort study evaluating safety and the role of therapeutic drug monitoring in minimizing toxicity. Pediatr Infect Dis J 30:827-832. http://dx.doi.org/10.1097 /INF.0b013e31821e405d.
14. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. 2004. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 114:e111-118. http://dx.doi.org/10.1542/peds .114.1.e111.
15. Rakhmanina NY, van den Anker JN. 2006. Pharmacological research in pediatrics: from neonates to adolescents. Adv Drug Deliv Rev 58:4-14. http://dx.doi.org/10.1016/j.addr.2005.12.001.
16. Dersch-Mills D, Akierman A, Alshaikh B, Yusuf K. 2012. Validation of a dosage individualization table for extended-interval gentamicin in neonates. Ann Pharmacother 46: 935-942. http://dx.doi.org/10.1345 /aph.1R029.
17. Turnidge J. 2003. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am 17:503528, v. http://dx.doi.org/10.1016/S0891 -5520(03)00057-6.
18. Mould DR, Upton RN. 2013. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2:e38. http://dx.doi.org/10.1038/psp.2013.14.
19. Marsot A, Boulamery A, Bruguerolle B, Simon N. 2012. Population pharmacokinetic analysis during the first 2 years of life: an overview. Clin Pharmacokinet 51:787-798. http://dx.doi.org/10.1007/s40262 -012-0015-8.
20. Schwartz GJ, Haycock GB, Edelmann CM, Jr, Spitzer A. 1976. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259-263.
21. Demczar DJ, Nafziger AN, Bertino JS, Jr. 1997. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother 41:1115-1119.
22. Mould DR, Upton RN. 2012. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol 1:e6. http://dx.doi.org/10.1038/psp.2012.4.
23. Sheiner LB, Beal SL. 1981. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512.
24. Williams PJ, Kim YH, Ette EI. 2007. The epistemology of pharmacometrics, p 223-245. In Ette EI, Williams PJ (ed), Pharmacometrics: the science of quantitative pharmacology. John Wiley & Sons, Hoboken, NJ.
25. World Health Organization. 2006. WHO child growth standards: Length/height-for-age, weight-for-age, weight-for-length, weight-forheight and body mass index-for-age: methods and development. World Health Organization, Geneva, Switzerland. http://www.who.int /childgrowth/standards/Technical-report.pdf?ua=1.
26. De Cock RFW, Piana C, Krekels EHJ, Danhof M, Allegaert K, Knibbe CAJ. 2011. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 67(Suppl 1):S5-S16. http://dx.doi.org/10 .1007/s00228-009-0782-9.
27. Xuan D, Nicolau DP, Nightingale CH. 2004. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Int J Antimicrob Agents 23: 291-295. http://dx.doi.org/10.1016 /j.ijantimicag.2003.07.010.
28. García B, Barcia E, Pérez F, Molina IT. 2006. Population pharmacokinetics of gentamicin in premature newborns. J Antimicrob Chemother 58:372-379. http://dx.doi.org/10.1093/jac/dkl244.
29. Koren G. 1997. Therapeutic drug monitoring principles in the neonate. National Academy of Clinical Biochemistry. Clin Chem 43:222-227.
30. Miron D. 2001. Once daily dosing of gentamicin in infants and children. Pediatr Infect Dis J 20:1169-1173. http://dx.doi.org/10.1097/00006454 -200112000-00016.
31. Bass KD, Larkin SE, Paap C, Haase GM. 1998. Pharmacokinetics of once-daily gentamicin dosing in pediatric patients. J Pediatr Surg 33: 1104-1107. http://dx.doi.org/10.1016/S0022-3468(98)90540-1.
32. Kraus DM, Pai MP, Rodvold KA. 2002. Efficacy and tolerability of extendedinterval aminoglycoside administration in pediatric patients. Paediatr Drugs 4:469-484. http://dx.doi.org/10.2165/00128072-200204070-00005.